Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Quantum BioPharma Ltd C.QNTM

Alternate Symbol(s):  QNTM

Healthcare
Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Its unbuzzd beverage is a proprietary formulation of vitamins and minerals to help with liver and brain function for the purposes of relieving the effects of alcohol consumption and restoring a normal lifestyle. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.


CSE:QNTM - Post by User

Quantum BioPharma Ltd > Biotechs didn’t need revenues to be worth billions
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1289)
•••
Comment by GrahamBon Nov 03, 2021 11:26am
106 Views
Post# 34082297

RE:Biotechs didn’t need revenues to be worth billions

RE:Biotechs didn’t need revenues to be worth billions
DavidRosenberg wrote: Don't always need revenues, they need results from trials 

https://www.toptal.com/finance/valuation/biotech-valuation



If you read the article, the key sentence is "track record of the company (its R&D and regulatory teams) in getting drugs approved"

Therin lies the reason why FSD is worth sub penny-it has no success in the area

The track record is abysmal
Shall I post it again?

  • "To calculate the probability of success for a drug candidate, as a general principle, we should be "good Bayesians," starting with a sensible base rate of success and then continuously adjusting for new evidence.
  • There are further potential adjustments to the base rate one could come up with, even such that do not have anything to do with the drug itself, such as the track record of the company (its R&D and regulatory teams) in getting drugs approved. There are also less trivial adjustments; for instance, imagine that a drug of a competitor, targeting perhaps the same pathway, runs into problems in a clinical trial."
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities